SILODOSIN
Substance profile for UNII CUZ39LUY82, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.
Substance Identity#
- UNII
- CUZ39LUY82
- Preferred term
- SILODOSIN
- Registry number
- 160970-54-7
- Ingredient type
- INGREDIENT SUBSTANCE
- Molecular formula
- C25H32F3N3O4
Chemical And Database Identifiers#
- InChIKey
- PNCPYILNMDWPEY-QGZVFWFLSA-N
- SMILES
- C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC3=CC=CC=C3OCC(F)(F)F
- RxCUI
- 720825
- PubChem
- 5312125
- NCIt
- C81372
- INN ID
- 8043
Open Chemistry Sources#
| Source | Identifier | Link |
|---|---|---|
| PubChem Compound | 5312125 | https://pubchem.ncbi.nlm.nih.gov/compound/5312125 |
| PubChem InChIKey Search | PNCPYILNMDWPEY-QGZVFWFLSA-N | https://pubchem.ncbi.nlm.nih.gov/#query=PNCPYILNMDWPEY-QGZVFWFLSA-N |
| RxNorm | 720825 | https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=720825 |
| NCI Thesaurus | C81372 | https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C81372 |
| FDA Substance Registration System | CUZ39LUY82 | https://precision.fda.gov/uniisearch/srs/unii/CUZ39LUY82 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| SILODOSIN | ACTIVE MOIETY | CUZ39LUY82 | RAPAFLO® (silodosin) Capsules These highlights do not include all the information needed to use RAPAFLO® safely and effectively. See full prescribing information for RAPAFLO. RAPAFLO® (silodosin) capsule for oral use Initial U.S. Approval: 2008 | 3 | |
| SILODOSIN | ACTIVE INGREDIENT | CUZ39LUY82 | RAPAFLO® (silodosin) Capsules These highlights do not include all the information needed to use RAPAFLO® safely and effectively. See full prescribing information for RAPAFLO. RAPAFLO® (silodosin) capsule for oral use Initial U.S. Approval: 2008 | 3 | |
| SILODOSIN | ACTIVE MOIETY | CUZ39LUY82 | RAPAFLO (SILODOSIN) CAPSULE [ACTAVIS PHARMA, INC.] | 20 | |
| SILODOSIN | ACTIVE INGREDIENT | CUZ39LUY82 | RAPAFLO (SILODOSIN) CAPSULE [ACTAVIS PHARMA, INC.] | 20 |